All In Biotech

Free tool

FAERS Monitor: Tradjenta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201280 or its brand name (Tradjenta, Linagliptin). Reports on generic versions are filed under their own applications.

Reports

18,487

Serious

13,056

71% of reports

Hospitalization

7,085

Death reported

1,717

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased1,385
  • diarrhoea1,322
  • nausea1,241
  • fatigue1,098
  • dyspnoea1,060
  • off label use1,019
  • dizziness997
  • vomiting976
  • acute kidney injury860
  • malaise843
  • headache810
  • pruritus788
  • arthralgia778
  • pyrexia758
  • pain702

Reports by year received

View as table
YearReports
20061
20102
2011206
2012698
2013589
2014818
20151,202
20161,404
20171,204
20181,281
20191,380
20201,169
20211,238
20221,636
20231,906
20241,457
20251,270
20261,026

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood glucose increasedSignal1,3858.48.09,061
acute kidney injurySignal8606.46.03,940
pyrexiaSignal7582.52.3688
vomitingSignal9762.42.2783
pruritusSignal7882.32.2610
diarrhoeaSignal1,3222.32.21,035
dizzinessSignal9972.32.1728
malaiseSignal8432.22.0554
dyspnoeaSignal1,0602.12.0653
arthralgiaSignal7782.12.0474
nausea1,2411.81.7444
fatigue1,0981.61.5259
headache8101.51.4125
off label use1,0191.31.284
pain7021.31.250

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.